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Abstract Interferon-induced transmembrane protein 1
(IFITM1) has recently been identified as a new molecular
marker in human colorectal cancer. However, its role in
glioma carcinogenesis is not known. In this study, we
demonstrated that suppression of IFITM1 expression sig-
nificantly inhibited proliferation of glioma cells in a time-
dependent manner. The growth inhibitory effect was
mediated by cell cycle arrest. Furthermore, IFITM1
knockdown significantly inhibited migration and invasion
of glioma cells, which could be attributed to decreased
expression and enzymatic activity of matrix metallopro-
teinase 9. Taken together, these results suggest that
IFITM1 is a potential therapeutic target for gliomas.
Keywords IFITM1  Glioma  Antiproliferation 
Anti-invasion  Cell cycle
Introduction
Glioma, derived from malignant glial cells, is the most
frequent tumor in the central nervous system. According to
its histopathological characteristics and clinical prognosis,
it is classified into four grades. Glioblastoma multiforme
(GBM), the grade IV glioma, is the most malignant type
and accounts for 60% of all brain tumor cases [1]. Glioma
cells are notorious for their rapid proliferation and wide-
spread invasion to surrounding normal brain tissues.
Despite recent advances in understanding the molecular
mechanism involved in glioma carcinogenesis, it remains
an untractable disease. Five-year survival in glioma is the
lowest among all tumor types, and median survival of
GBM is only 10–12 months [2, 3]. A major breakthrough
in glioma treatment clearly requires the discovery of novel
target-based molecules based on our improved under-
standing of the molecular pathogenesis of glioma.
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Interferon-induced transmembrane protein 1 (IFITM1),
also known as 9–27, CD225, and Leu13, is a member of the
interferon-induced transmembrane protein family. IFITM1
is a component in the membrane complex that transduces
antiproliferative and homotypic adhesion signals in lym-
phocytes [4, 5]. It is also responsible for mouse primordial
germ cell development [6, 7]. Furthermore, it has been
shown to promote cancer progression by enhancing cell
migration and invasion in gastric cancer and head and neck
cancer [8, 9]. Recently, Seyfried et al. identified several
novel brain tumor membrane biomarkers using liquid
chromatography coupled with tandem mass spectrometry.
Among the 25 differentially regulated membrane proteins,
expression of IFITM1 was found to be significantly higher
in CT-2A astrocytoma cells than in terminally differenti-
ated mouse astrocytes [10], suggesting that it might be
involved in the neoplasia process of gliomas. In the present
study, therefore, we examined the oncogenic roles of
IFITM1 in human glioma cells.
Materials and methods
Cell culture and reagents
Human high-grade glioma cell lines (U-87 MG, U-373 MG,
U-138 MG, SW1088) were obtained from the American
Type Culture Collection (ATCC, Manassas, VA). Cell line
LN-308 was a gift from Dr. M.E. Hegi (University Hospital
Lausanne, Switzerland). The cells were maintained in
minimum essential medium (MEM; Invitrogen; for U-87
MG, U-373 MG, U-138 MG, and LN-308) or Leibovitz’s
L-15 medium (Invitrogen, for SW1088) supplemented with
10% fetal bovine serum (FBS; Invitrogen) under 5% CO2 at
37C.
Small interfering RNA (siRNA) duplex oligonucleotides
specifically targeting human IFITM1 messenger RNA
(mRNA) (siIFITM1; 50-AACTCATGACCATTGGATTC
A-30) or firefly luciferase mRNA (siLuc; 50-AACGTAC
GCGGAATACTTCGA-30) were synthesized and purified
by Sigma-Proligo (The Woodlands, TX, USA). All anti-
bodies used in this study were bought from Santa Cruz
Biotechnology (Santa Cruz, CA).
Semiquantitative reverse-transcription polymerase
chain reaction (RT-PCR)
Total RNA was extracted from the five glioma cell lines
with the use of RNeasy mini kit (Qiagen). First-strand
complementary DNA (cDNA) was reverse-transcribed by
SuperScript First-Strand cDNA System (Invitrogen) and
was amplified by PCR. The PCR conditions were set up as
follows: 45 s at 95C, 45 s at 55C, and 1 min at 72C for
30 cycles (for IFITM1) or for 22 cycles [for glyceraldehyde
3-phosphate dehydrogenase (GAPDH)].
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay
One day before transfection, 3 9 104 U-373 MG or U-87
MG cells in 100 ll growth medium were each seeded onto
96-well cell culture plate. The cells were transfected with
siIFITM1 or siLuc at final concentration of 100 nM and
oligofectamine transfection reagent (Invitrogen). Cells incu-
bated with opti-MEM and transfection reagent were used as a
negative control (mock transfection). At 24, 48 or 72 h after
transfection, 10 ll sterile MTT dye (5 mg/ml; Sigma,
St. Louis, MO) was added to each well. After 4 h incubation
at 37C, the MTT solution was replaced with 100 ll dime-
thyl sulfoxide (DMSO). Spectrometric absorbance at
570 nm was measured with the use of a microplate reader
(Spectra Max 340, Molecular Devices, Sunnyvale, CA).
Wound healing assay
Equal numbers (1.5 9 105) of U-373 MG or U-87 MG
cells transfected by 100 nM siIFITM1 or siLuc for 24 h
were treated with 0.25% trypsin-ethylenediamine tetra-
acetic acid (EDTA; Invitrogen) and plated onto a 48-well
plate at 1 9 105 cells per well. When 90% confluence
was reached, a single wound was created by gently
scratching the attached cells using a sterile plastic pipette
tip. Debris was removed by washing the cells with
serum-free medium. Immediately or 24 h after incubation
at 37C, phase-contrast images were photographed digi-
tally. The cells that migrated to the wounded area, or
those with extended protrusion from the borders of the
wound, were counted from three randomly selected areas
per well. The experiment was performed for three times
in triplicates.
In vitro invasion assay
Equal numbers (3 9 104) of U-373 MG or U-87 MG cells
transfected by 100 nM siIFITM1 or siLuc for 24 h were
plated onto a 24-well cell culture insert coated with Ma-
trigel with 8-lm pores (Becton Dickinson Labware, Bed-
ford, MA). MEM with 10% FBS was added to the lower
chamber as chemoattractant. After incubation for 22 h, the
cells on the upper surface of the Matrigel membrane were
removed. The penetrated cells on the lower surface of the
membrane were fixed with 100% methanol, stained with
1% toluidine (Sigma), and quantified in five randomly
selected areas per insert. The experiment was performed
for three times in triplicates.
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Cell cycle analysis
One day before transfection, 1.5 9 105 U-373 MG or U-87
MG cells were seeded onto six-well cell culture plates. The
cells were transfected with siIFITM1 or siLuc at final
concentration of 100 nM using oligofectamine transfection
reagent (Invitrogen) for 72 h. The transfected cells were
fixed in ice-cold 70% ethanol and stained by Coulter DNA-
Prep Reagents Kit (Beckman Coulter, Fullerton, CA).
Cellular DNA content of 5 9 105 cells from each sample
was determined with the use of an EPICS ALTRA flow
cytometer (Beckman Coulter). Cell cycle phase distribu-
tions were analyzed by ModFit LT 2.0 software (Verify
Software House, Topsham, ME) using the data obtained
from three separate experiments in which each transfection
was done in triplicate.
Real-time RT-PCR
Total RNA was extracted from U-373 MG cells transfected
by siIFITM1 or siLuc for 72 h using RNeasy mini kit
(Qiagen). First-strand cDNA was reverse-transcribed from
1 lg total RNA using the Super-Script First-Strand cDNA
System (Invitrogen) and amplified by Platinum SYBR
Green qPCR SuperMix-UDG (Invitrogen). A master mix
was prepared for each PCR reaction, which included
Platinum SYBR Green qPCR SuperMix-UDG, forward
primer, reverse primer, and 10 ng template cDNA. PCR
conditions were 2 min at 50C and 10 min at 95C, fol-
lowed by 40 cycles of 95C for 15 s, 58C for 60 s, and
95C for 15 s. The data was analyzed by calculating the Ct
values by the use of the formula 2 - (B1 - A1), where B1
is the Ct value of the amplified genes and A1 is the Ct value
of GAPDH.
Western blotting
For Western blotting analysis, U-373 MG and U-87 MG
cells transfected by siIFITM1 or siLuc for 24, 48, and 72 h
were washed twice with ice-cold phosphate-buffered saline
(PBS) and lysed for 30 min in a radioimmunoprecipitation
assay lysis buffer [50 mM Tris-HCl, 1% NP-40, 0.5%
sodium deoxycholate, 150 mM sodium chloride, 0.1%
sodium dodecyl sulfate (SDS)] containing 1 mM phenyl-
methylsulfonyl fluoride and protease inhibitor cocktail
(Sigma). The lysates were centrifuged at 14,000 9 g for
20 min, and the supernatants were removed. The protein
concentrations of the supernatants were determined by using
a bicinchoninic acid protein assay kit (Pierce, Rockford, IL).
Heat-denatured protein samples (40 lg per lane) were
resolved by SDS-polyacrylamide gel electrophoresis
(PAGE) (4% stacking gel and 12% separating gel) and
transferred to nitrocellulose membranes (Amersham Bio-
sciences, Piscataway, NJ). The membranes were incubated
with 5% milk for 2 h to block nonspecific binding, followed
by incubation with a primary goat antibody against human
IFITM1, or primary mouse antibodies against human
cyclin D1, cyclin-dependent kinase 2 (CDK2), cyclin-
dependent kinase inhibitor 1B (p27kip1), matrix metallopro-
teinase 9 (MMP9), cyclin B1, cyclin-dependent kinase 1
(CDK1), and b-actin, respectively. The membranes were
washed three times for 30 min in Tris-buffered saline (TBS)
with 0.1% Tween 20 and then incubated with the corre-
sponding secondary antibodies. The membranes were
washed thoroughly in TBS with 0.1% Tween 20 and the
bound antibodies were detected with enhanced chemilumi-
nescence detection reagents (Amersham Bioscience, Pis-
cataway, NJ) according to the manufacturer’s instructions.
Band intensity was quantified with the use of ImageQuant
software (Molecular Dynamics, Sunnyvale, CA).
Gelatin zymography
U-373 MG cells transfected by siIFITM1 or siLuc for 48 h
were first washed twice with serum-free medium and then
cultured with the same medium for additional 24 h. The
medium was collected and clarified by centrifugation to
remove cells and debris. The supernatants were removed,
and the protein concentrations of the supernatants were
determined by using a bicinchoninic acid protein assay kit
(Pierce, Rockford, IL). Samples were prepared by mixing
the supernatants with an equal volume of 29 nonreducing
loading buffer for 15 min at room temperature. Samples
(15 lg per lane) were resolved by 10% polyacrylamide gel
containing 1 mg/ml gelatin. After electrophoresis, the gel
was washed twice in 2.5% Triton X-100 for 30 min at
room temperature. The gel was then incubated with
developing buffer (50 mM Tris-HCl, pH 7.4; 10 mmol/l
CaCl2) overnight at room temperature, stained with Coo-
massie Brilliant Blue (0.25% w/v), and then destained in
methanol:acetic acid:water solution (45:10:45). A clear
zone indicates the presence of gelatinolytic activity in
zymography.
Statistical analysis
All experiments were performed three times in triplicates.
The data were analyzed by Student’s t test (Prism 3.0,
GraphPad Software, San Diego, CA) and are expressed as
mean ± standard deviation (SD). Differences were con-
sidered statistically significant at P value \0.05.
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Results
Expression of IFITM1 in human glioma cell lines
mRNA and protein levels of IFITM1 in five human glioma
cell lines (U-87 MG, U-373 MG, U-138 MG, SW1088, and
LN-308; grades II–IV) were analyzed by RT-PCR and
Western blotting, respectively. IFITM1 was expressed in all
five glioma cell lines, and IFITM1 protein levels were gen-
erally consistent with mRNA levels (Fig. 1). According to
data from ATCC (http://www.atcc.org/), the four cell lines
with higher IFITM1 expression are all tumorigenic in nude
mice. By contrast, U-138 MG, which displayed the lowest level
of IFITM1 level, was the only nontumorigenic cell line tested.
Effect of IFITM1 knockdown on the growth
of glioma cells
To elucidate the functional role of IFITM1 in glioma car-
cinogenesis, we examined the effect of IFITM1 mRNA
knockdown on glioma cell growth in vitro by transfecting
U-373 MG or U-87 MG cells with siIFITM1 (which spe-
cifically targets IFITM1 mRNA), siLuc (which targets an
unrelated firefly luciferase mRNA) or transfection reagent
alone (mock transfection). U-373 MG and U-87 MG cell
lines were chosen as our cell model, because they both
showed a high level of IFITM1 expression and are widely
used tumorigenic cell lines in glioma study. Our Western
blotting data showed that the inhibitory effect of siIFITM1
on IFITM1 expression was time dependent and most
effective at 72 h after transfection in U-373 MG or U-87
MG cells (Fig. 2a). Thus, 72 h was chosen as the time
point for siIFITM1 transfection in subsequent experiments.
We next determined the numbers of viable cells at various
time intervals after siIFITM1 or siLuc transfection, using
MTT assays. Transfection with siIFITM1, but not siLuc,
statistically significantly inhibited growth of U-373 MG and
U-87 MG cells in a time-dependent manner (Fig. 2b).
Effect of IFITM1 knockdown on cell migration
and invasion in vitro in glioma cells
To examine the effect of IFITM1 knockdown on glioma
cell migration, wound healing assay was performed using
U-373 MG or U-87 MG cells transfected with siIFITM1 or
siLuc. Immediately or 24 h after incubation, the cells that
migrated to the wounded area, or those with extended
protrusion from the borders of the wound, were counted
from three randomly selected areas per well. Our data
showed that siIFITM1 transfection markedly inhibited
migration of U-373 MG and U-87 MG cells (Fig. 3a). To
examine the effect of IFITM1 knockdown on glioma cell
invasion, in vitro invasion assay was performed. After
incubation for 22 h, the penetrated cells on the lower sur-
face of the membrane were quantified in five randomly
selected areas per insert. Our data showed that transfection
with siIFITM1 significantly suppressed invasion of U-373
MG and U-87 MG cells (Fig. 3b).
Effect of IFITM1 knockdown on cell cycle
progression in glioma cells
To better understand the mechanism of siIFITM1-induced
cell growth inhibition, we performed flow cytometry to
examine the cell cycle profiles of U-373 MG cells or
U-87 MG cells transfected with siIFITM1 or siLuc. The
Fig. 1 Expression of IFITM1 in five human glioma cell lines.
a Representative agarose gel pictures showing expression of IFITM1
in five glioma cell lines as measured by semiquantitative RT-PCR.
The bar graph shows GAPDH-normalized IFITM mRNA expression
in those cell lines. b Western blotting analysis showing protein levels
of IFITM1 in five glioma cell lines. The bar graph shows b-actin-
normalized IFITM protein expression in those cell lines. The
intensities of the results were quantified by densitometry and
ImageQuant software (molecular dynamics). Tumorigenic and non-
tumorigenic glioma cell lines are labeled ‘‘?’’ and ‘‘-’’, respectively
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siIFITM1-transfected U-373 MG cells had a higher
number of cells at G0–G1 phase and a lower number of
cells at S and G2–M phases. On the other hand, the siI-
FITM1-transfected U-87 MG cells had a higher popula-
tion of cells at G2–M phase (Fig. 4), suggesting that the
effect of growth inhibition induced by siIFITM1 in gli-
oma cells was mediated by cell cycle arrest at either G0–
G1 or G2–M phase.
Effect of IFITM1 knockdown on expression of cell-
cycle-related genes and expression and activity
of matrix metalloproteinase 9 (MMP9) in glioma cells
To investigate the signaling of IFITM1-induced cell cycle
arrest and cell invasion inhibition, we examined the effect of
IFITM1 suppression on well-documented genes related to
cell cycle control (cyclin A, cyclin B1, cyclin D1, cyclin E,
CDK2, CDK4, p21, and p27kip1) and cell invasion [MMP2,
MMP9, tissue inhibitor of metalloproteinase-1 (TIMP1), and
TIMP2] by real-time RT-PCR in U-373 MG cells transfected
with siIFITM1. The relative mRNA levels (normalized by
mRNA level of GAPDH) of cyclin A, cyclin B1, cyclin D1,
cyclin E, CDK2, CDK4, and MMP9 were significantly
reduced in siIFITM1-transfected cells at 72 h after
transfection (the mean fold changes of the genes were
-1.8 ± 0.15, -2.5 ± 0.43, -4.9 ± 0.6, -1.5 ± 0.28,
-1.7 ± 1.0, -1.5 ± 0.5, and -4.6 ± 0.15, respectively).
On the contrary, the relative mRNA level of p27kip1 was
significantly increased, with mean fold change of 1.6 ± 0.2
(Fig. 5a).
We next examined protein levels of cyclin D1, CDK2,
and p27kip1 in U-373 MG cells at 72 h after siIFITM1 or
siLuc transfection. Consistent with the real-time RT-PCR
results, the relative protein levels (normalized by b-actin
protein expression) of cyclin D1 and CDK2 were reduced,
whereas the relative protein level of p27kip1 was increased
by siIFITM1 transfection (Fig. 5b).
The inhibitory effect of IFITM1 on cell cycle progression
was different in U-373 MG cells and U-87 MG cells. To
explain the discrepancy, we also examined the protein
levels of cyclin D1, CDK2, p27kip1, cyclin B1, and CDK1
in U-87 MG cells at 72 h after siIFITM1 or siLuc trans-
fection. Our results showed that the relative protein levels
(normalized by b-actin protein expression) of cyclin D1 and
p27kip1 were increased, whereas the relative protein levels
of CDK1 was reduced by siIFITM1 transfection (Fig. 5c).
Finally, the protein level and enzymatic activity of
MMP9 were measured at 72 h after transfection by
Fig. 2 Effect of IFITM1
knockdown on glioma cell
growth. a Western blotting
analysis showing the time-
dependent effect of siIFITM1
transfection on levels of
IFITM1 and b-actin expression
in U-373 MG cells (left) and
U-87 MG cells (right). The bar
graph shows relative IFITM1
protein expression levels
expressed as percentage of
IFITM1 expression in control
cells transfected with siLuc.
* P \ 0.05. b MTT assays
showing the time-dependent
effect of siIFITM1 transfection
on U-373 MG cells (left) and
U-87 MG cells (right).
OD570 nm values obtained at
24 h post transfection were
normalized as 1. * P \ 0.001
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Western blotting and gelatin zymography, respectively.
The relative protein level of MMP9 in siIFITM1-trans-
fected cells was significantly lower than that in siLuc-
transfected U-373 MG cells. The gelatin zymography assay
also detected a weaker lytic zone at the molecular mass
corresponding to MMP9 in the siIFITM1-transfected cells
(Fig. 5d).
Discussion
The role of IFITM1 in carcinogenesis is unclear. Never-
theless, recent IFITM1 expression data in different cancer
types have led us to hypothesize that it might possess
oncogenic function; for instance, IFITM1 expression has
been found to be greatly elevated in colon cancer [11],
cervical cancer [12], esophageal cancer [13], ovarian can-
cer, and mouse astrocytoma [10, 14]. In this study, we
determined IFITM1 expression levels in five human glioma
cell lines and investigated its roles in proliferation,
migration, and invasion glioma cells. Our results showed
that IFITM1 was expressed in the five human glioma cell
lines, and its expressions were positively correlated with
their tumorigenicity. Suppression of IFITM1 by siIFITM1
transfection inhibited proliferation, migration, and invasion
of U-373 MG and U-87 MG glioma cells. Together, these
Fig. 3 Effect of IFITM1 knockdown on glioma cell migration and
invasion in vitro. a Wound healing assays showing the inhibitory
effect of siIFITM1 on migration of U-373 MG and U-87 MG cells.
The bar graph shows mean migrated cells at 24 h after wound
formation. * P \ 0.01. b In vitro Matrigel assays showing the
inhibitory effect of siIFITM1 on invasion of U-373 MG and U-87
MG cells. The bar graph indicates the mean number of invaded cells
at 22 h after cell seeding. * P \ 0.01; ** P = 0.0031
U-373 MG 
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Fig. 4 Effect of siIFITM1 on
cell cycle progression of glioma
cells. U-373 MG cells (left) or
U-87 MG cells (right)
transfected with siIFITM1 or
siLuc were collected 72 h post
transfection and subjected to
flow cytometry analysis. Data
are presented as mean ± SD
from three independent
experiments. * P \ 0.01,
** P = 0.0015
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Fig. 5 Effect of IFITM1
knockdown on expression of
cell-cycle-related genes and
expression and activity of MMP
in glioma cells. a Real-time
RT-PCR showing the effect of
siIFITM1 on mRNA levels of
genes related to cell cycle
control (cyclin A, cyclin B1,
cyclin D1, cyclin E, CDK2,
CDK4, p21, and p27kip1) and
cell invasion (MMP2, MMP9,
TIMP1, and TIMP2). Dashed
horizontal lines indicate relative
mRNA levels normalized by
GAPDH mRNA expression
at ±1.5-fold. Expression levels
below -1.5-fold were regarded
as decreased expression,
whereas those above 1.5-fold
were regarded as increased
expression. b Western blotting
analysis showing the effect of
siIFITM1 on expression levels
of IFITM1, cyclin D1, CDK2,
p27kip1, and b-actin in U-373
MG cells. The bar graph shows
relative IFITM1, cyclin D1,
CDK2, and p27kip1 protein
levels in siIFITM1-transfected
cells versus those in control
siLuc-transfected cells.
* P = 0.033, ** P \ 0.01.
c Western blotting analysis
showing the effect of siIFITM1
on expression levels of IFITM1,
cyclin D1, CDK2, p27kip1,
cyclin B1, CDK1, and b-actin
in U-87 MG cells. The bar
graph shows relative IFITM1,
cyclin D1, CDK2, p27kip1,
cyclin B1, and CDK1 protein
levels in siIFITM1-transfected
cells versus those in control
siLuc-transfected cells.
* P = 0.006, ** P \ 0.05.
d Western blotting analysis and
gelatin zymography assays
showing the effect of siIFITM1
on MMP9 expression and
enzymatic activity in U-373 MG
cells. The bar graph shows the
relative integrated densities of
the bands in siIFITM1-
transfected cells expressed as
percentage values of those in
control siLuc-transfected cells.
* P = 0.0095, ** P \ 0.001
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findings suggest for the first time that IFITM1 might be a
potential candidate oncogene in glioma.
Our flow cytometry data showed that the growth inhibi-
tory effect of siIFITM1 was mediated by cell cycle arrest. Of
note, the siIFITM1-transfected U-373 MG cells displayed
G0–G1 phase arrest, which could be mediated via decreased
expression of G1/S-specific cyclin D1 and CDK2, and
increased expression of p27kip1 (Fig. 5b). By contrast, the
siIFITM1-transfected U-87 MG cells showed G2–M phase
arrest, which could be mediated by increased expression of
cyclin D1 and p27kip1, and decreased expression of CDK1.
Furthermore, this discrepancy may be explained by the fact
that U-373 MG cells express mutant p53, whereas U-87 MG
cells possess wild-type p53 [15]. Because p53 is required for
both G0–G1 and G2–M phase transitions [16], and the
Gadd45-mediated G2–M arrest was wild-type p53-depen-
dent [17], a significantly smaller number of siIFITM1-
transfected U-373 MG cells should be able to enter the S
phase and progress to the G2–M phase. As a result, U-373
MG cells and U-87 MG cells arrested at different cell cycle
checkpoints after siIFITM1 transfection.
Metastasis is one of the hallmarks of malignant cancers.
Degradation of basement membranes and stromal extra-
cellular matrix (ECM) is an initial step for metastasis. To
this end, matrix metalloproteinases (MMPs) play a crucial
role to degrade the physical barrier of ECM. Furthermore,
MMPs are required to maintain a microenvironment for
growth, invasion, and angiogenesis of tumor cells [18].
MMP9, a member of the MMP protein family, can degrade
both denatured collagen and type IV collagen. MMP9
activity was also reported to be closely correlated with
glioma progression [19]. Consistent with these findings,
our results showed that IFITM1 knockdown significantly
inhibited migration and invasion of glioma cells, and the
inhibition was associated with reduced expression and
activity of MMP9.
IFITM1 is commonly considered as a protein induced by
interferon a and c [20, 21], and it is involved in signal
transduction of antiviral, anti-inflammation, and antipro-
liferation activities mediated by interferons in our immune
system [22, 23]. However, with the improved understand-
ing of the natural immune response to cancer, the roles of
interferons in carcinogenesis are different from previously
recognized. The relationship between the host immune
system and cancer includes three phases, namely elimina-
tion, equilibrium, and escape. Interferons act as central
coordinators between the interaction of the host immune
system and cancer cells. At the elimination phase, inter-
feron a and c are released by the host immune system in
response to tumor-specific antigens and help to destroy
nascent transformed cells. Tumor cells that are not killed at
the first phase can then progress to the equilibrium phase.
When the balance is broken by immune inhibition or
emergence of tumor-cell variants, the escape phase begins,
where the cancer cells escape the mechanisms that operate
to suppress them and they become clinically detectable and
grow progressively [24, 25]. In contrast to the elimination
phase, the escape phase is poorly understood. Yang et al.
[8] reported that gastric cancer cells overexpressing
IFITM1 were more resistant to natural killer cells. Thus,
we proposed that, under the influence of interferons at the
escape phase, IFITM1 may be produced by glioma cells so
as to antagonize the attack by the host immune system by
promoting cell proliferation and invasion.
In summary, the data presented here provide the first
evidence that IFITM1 is expressed in human glioma cell
lines. Suppression of IFITM1 expression by siIFITM1
inhibited proliferation of glioma cells by arresting cell
cycle progression. We further showed that siIFITM1
transfection inhibited migration and invasion of glioma
cells by decreased expression and activity of MMP9.
Therefore, our data suggest that IFITM1 is a potential
therapeutic target for malignant gliomas.
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